25+ year industry executive to oversee Tessa’s financial management, investor relations, and business development strategy
SINGAPORE, April 5 (Bernama-GLOBE NEWSWIRE) —Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the appointment of Wilson W. Cheung as its chief financial officer effective April 1, 2022. Mr. Cheung brings to Tessa more than 25 years of experience in accounting and corporate finance, compliance, and corporate leadership at both public and private companies with presence in both the U.S. and China. He joins Tessa as the Company is advancing the clinical exploration of its autologous CD30-CAR-T therapy (TT11) and its allogeneic CD30.CAR EBVST therapy (TT11X) programs.